Skip to main content
Heritage Bio Labs · Research use only
Heritage Bio Labs

GLP-1 SEMAExplore study findings

What three semaglutide trials tell us about kidney outcomes

2 numbered sourcesSource years 2026

Peptides are short amino-acid chains joined by peptide bonds. Some mimic hormones and activate the same receptors. Semaglutide is a modified peptide that activates the glucagon-like peptide-1, or GLP-1, receptor. It is used in several approved formulations for specific conditions. A 2026 analysis pooled data from three trials to ask how often serious kidney-related events occurred in people assigned to semaglutide or placebo. [1, 2]

The analysis included more than 30,000 participants from SELECT, FLOW and SOUL. FLOW enrolled people with type 2 diabetes and chronic kidney disease. SELECT and SOUL enrolled people with atherosclerotic cardiovascular disease, and their eligibility criteria differed. The trials also studied different semaglutide formulations or strengths. Pooling the participant-level data gave investigators more events to analyze and let them examine a broader population. It also meant that the combined estimate represented several trial settings and versions of the treatment. [1]

The main measure was time until the first of several specified events. These included a large persistent decline in estimated kidney filtration, kidney failure, kidney-related death or cardiovascular-related death. The event counts were 973 in the semaglutide groups and 1,134 in the placebo groups. The hazard ratio was 0.84, with a 95% confidence interval of 0.77 to 0.91. The hazard ratio compares the event rates over follow-up under the statistical model. It does not mean that 16 out of every 100 people avoided an event. [1]

The investigators also examined a narrower outcome that excluded cardiovascular death. For that measure the estimated hazard ratio was 0.80, and the uncertainty interval again excluded one. Reporting that result helps the reader see whether the pooled finding depended entirely on counting cardiovascular deaths within the main outcome. It also gives a sense of how the results change when the definition of an event changes. The pooled estimate cannot identify a precise effect for every combination of kidney function, diabetes status and formulation. [1]

The analysis brings together clinical outcomes from randomized studies, which goes beyond measuring short-term changes in blood sugar or weight. Its estimates describe people with the conditions studied and the treatments specified in the protocols. Product approvals remain tied to particular formulations, indications and patient populations. A pooled estimate across trials can inform the broader scientific question about semaglutide and kidney outcomes. A label is the separate source for determining what a particular product is approved to treat. [1, 2]

Sources

Original works cited in this article. Links open the external record in a new tab.

Shop GLP-1 SEMA

Articles from the Heritage Bio Labs research series, with links to the original sources. For research use only; not medical advice. Also available as Markdown or JSON.